Progress and prospect of regulatory science in cell and gene therapy productsGAO Jian-chao, WEI Wei, ZHANG Min, GAO Chen-yan105-108
Regulatory considerations for using surrogate endpoints to accelerate the development of COVID-19 vaccinesYANG Jing-shu, DING Sheng, YANG Yue119-124
Research on the new drug marketing approval procedures based on surrogate endpoints in the US and EU and its enlightenment to ChinaYANG Li, WEI Yan-yi, WU Di, CHEN Yu-wen, WANG Zu-guang, YANG Ze-ying132-141
Application of patient-reported outcome measurement tools in drug development and regulatory approval in the USGUAN Hong-feng, YANG Li-na, YANG Yue142-146
Regulatory considerations about accelerating the approval of domestic HPV vaccinesYANG Jing-shu, DING Sheng, ZHANG Ya-juan, YANG Yue147-154
Analysis of China regulatory strategy on post-approval changes of pharmaceutical productsLI Cheng, CHEN Gui-liang155-159
Study on data management requirements of drug pre-approval inspectionYAN Ruo-xi, CAO Yi, DONG Jiang-ping160-164
Analysis of some characteristics and management of drug changes in the whole life cycleLI Shuai, MEI Ni, CHEN Gui-liang165-171
Consideration on formulation and implementation of administrative documents ICH M4 Module 1 of ChinaXIAO Fang, WEN Bao-shu, HE Yu-hong, DU Hai-ru, SUN Tao, YU Hong, ZHAI Yun, ZHOU Heng, XIE Song-mei172-176